| Literature DB >> 32489176 |
Max Augustin1,2,3,4, Philipp Schommers1,2,4,5, Isabelle Suárez1,2,4, Philipp Koehler1,3,6, Henning Gruell2,5, Florian Klein2,3,5, Christian Maurer7, Petra Langerbeins7, Vanessa Priesner1, Kirsten Schmidt-Hellerau1, Jakob J Malin1,2,3, Melanie Stecher1,2, Norma Jung1, Gerhard Wiesmüller8, Arne Meissner9, Janine Zweigner9, Georg Langebartels10, Felix Kolibay10, Victor Suárez11, Volker Burst11, Philippe Valentin11, Dirk Schedler12, Oliver A Cornely1,2,3,6, Michael Hallek3,7, Gerd Fätkenheuer1,2, Jan Rybniker1,2,3,4, Clara Lehmann1,2,3,4.
Abstract
The coronavirus disease (COVID-19) pandemic has caused tremendous pressure on hospital infrastructures such as emergency rooms (ER) and outpatient departments. To avoid malfunctioning of critical services because of large numbers of potentially infected patients seeking consultation, we established a COVID-19 rapid response infrastructure (CRRI), which instantly restored ER functionality. The CRRI was also used for testing of hospital personnel, provided epidemiological data and was a highly effective response to increasing numbers of suspected COVID-19 cases.Entities:
Keywords: COVID-19; SARS-CoV-2; outbreak; pandemic preparedness; risk assessment
Mesh:
Year: 2020 PMID: 32489176 PMCID: PMC7268272 DOI: 10.2807/1560-7917.ES.2020.25.21.2000531
Source DB: PubMed Journal: Euro Surveill ISSN: 1025-496X
Figure 1COVID-19 rapid response infrastructure at University Hospital Cologne, North Rhine Westphalia, Germany, February 2020
Figure 2Consultations (A) and tested patients (B) at the COVID-19 rapid response infrastructure at University Hospital Cologne, North Rhine Westphalia, Germany, 27 February–12 March 2020
Characteristics of SARS-CoV-2-tested individuals at the COVID-19 rapid response infrastructure at University Hospital Cologne and predictors for positive test results by univariable and multivariable logistic regression analysis, North Rhine Westphalia, Germany, 27 February–12 March 2020 (n = 746)
| SARS-CoV-2 positive n = 73 | SARS-CoV-2 negative n = 673 | Univariable regressiona | Multivariable regressiona | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | Median | IQR | n | % | Median | IQR | OR | 95% CI | p value | OR | 95% CI | p value | |
|
| 45 | 62 | NA | NA | 320 | 48 | NA | NA | 1.78 | 1.09–2.91 | 0.023 | 1.85 | 1.00–3.42 | 0.05 |
|
| NA | NA | 43 | 35–54 | NA | NA | 35 | 27–48 | 1.04 | 10.3–1.06 | < 0.001 | 1.05 | 1.03–1.07 | < 0.001 |
| Risk factor | ||||||||||||||
| Contactb | 37 | 51 | NA | NA | 319 | 47 | NA | NA | 2.46 | 1.07–5.67 | 0.035 | 3.09 | 1.21–7.90 | 0.018 |
| Areac | 32 | 44 | NA | NA | 188 | 28 | NA | NA | 3.97 | 1.70–9.22 | 0.001 | 4.19 | 1.63–10.8 | 0.003 |
| None | 4 | 6 | NA | NA | 166 | 25 | NA | NA | ref | ref | NA | ref | ref | NA |
| Symptomsd,e | ||||||||||||||
| Yes | 67 | 92 | NA | NA | 483 | 72 | NA | NA | 4.39 | 1.87–11.0 | 0.001 | d | d | NA |
| Days since onset of symptomsf | NA | NA | 3 | 1–5 | NA | NA | 4 | 2–7 | 0.89 | 0.81–0.97 | 0.007 | 0.87 | 0.78–0.96 | 0.008 |
| Cough | 54 | 74 | NA | NA | 353 | 53 | NA | NA | 2.58 | 1.49–4.45 | 0.001 | 1.73 | 0.79–3.89 | 0.173 |
| Muscle or body aches | 33 | 45 | NA | NA | 88 | 13 | NA | NA | 5.49 | 3.29–9.16 | < 0.001 | 3.85 | 2.02–7.34 | < 0.001 |
| Fever | 28 | 38 | NA | NA | 114 | 17 | NA | NA | 3.05 | 1.83–5.10 | < 0.001 | 2.14 | 1.12–4.05 | 0.02 |
| Headache | 23 | 32 | NA | NA | 129 | 19 | NA | NA | 1.94 | 1.14–3.30 | 0.014 | 1.09 | 0.57–2.11 | 0.779 |
| Sore throat | 22 | 30 | NA | NA | 245 | 36 | NA | NA | 0.76 | 0.45–1.27 | 0.29 | 0.77 | 0.35–1.17 | 0.499 |
| Rhinitis | 20 | 27 | NA | NA | 240 | 36 | NA | NA | 0.69 | 0.39–1.17 | 0.161 | 0.47 | 0.21–1.02 | 0.054 |
| Abnormal fatigue | 7 | 9 | NA | NA | 58 | 9 | NA | NA | 1.13 | 0.49–2.56 | 0.78 | 0.61 | 0.23–1.60 | 0.316 |
CI: confidence interval; COVID-19: coronavirus disease; IQR: interquartile range; NA: Not applicable; OR: odds ratio; ref: reference category; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.
a Uni- and multivariable logistic regression was performed. The final multivariable regression was performed using the enter methods (no cut-off) with variables for sex, age, risk for transmission, days since onset of symptoms, fever, cough, cold, sore throat, muscle or body aches, headache, and abnormal fatigue.
b Contact to a laboratory-confirmed COVID-19 case in the last 14 days [5].
c Visited an area at risk in the last 14 days [5].
d Excluded due to multicollinearity.
e Reference is no symptom for each category.
f Missing for 51 individuals (n = 49 SARS-CoV-2 negative and n = 2 SARS-CoV-2 positive).
Figure 3Early extension of risk areas at the COVID-19 rapid response infrastructure, University Hospital Cologne, Germany, February 2020